MD-3-A45

Cat. No.: HY-186173: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MD-3-A45 is an inhibitor of fibroblast growth factor 23 (FGF-23). MD-3-A45 blocks the activation of the FGFRs/α-klotho signaling pathway by FGF-23 and inhibits FGF-23-induced ERK activation. MD-3-A45 can be used in the research of chronic kidney disease, hereditary hypophosphatemic rickets and acquired hypophosphatemic rickets.

For research use only. We do not sell to patients.

MD-3-A45 Chemical Structure

CAS No. : 2314337-87-4

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	EC₅₀	6.9 10^2 μM Compound: 13a	Cytotoxicity against HEK293T cells assessed as effect on LDH release measured after 5 hrs by CytoTox96 Non-Radioactive assay Cytotoxicity against HEK293T cells assessed as effect on LDH release measured after 5 hrs by CytoTox96 Non-Radioactive assay	[PMID: 33232874]

In Vitro

MD-3-A45 completely inhibits FGF-23-induced ERK activation in HEK-293 cells expressing FGFRs/α-Klotho with an IC₅₀ of 0.14 μM, and has a metabolic stability half-life of 9 minutes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

237.30

Formula

C₁₆H₁₅NO

CAS No.

2314337-87-4

Appearance

Solid

Color

Off-white to light brown

SMILES

O/N=C/C1=C(/C=C/C2=CC=C(C)C=C2)C=CC=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (210.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.2141 mL	21.0704 mL	42.1407 mL
5 mM	0.8428 mL	4.2141 mL	8.4281 mL
10 mM	0.4214 mL	2.1070 mL	4.2141 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.9%

Select Batch:

Data Sheet (273 KB) SDS (252 KB)

COA (249 KB) HNMR (200 KB) LCMS (112 KB)

Handling Instructions (2659 KB)

References

[1]. Jerome Baudry, et al. Fibroblast growth factor 23 antagonists and related compositions and methods. WO2019084476.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.2141 mL	21.0704 mL	42.1407 mL	105.3519 mL
	5 mM	0.8428 mL	4.2141 mL	8.4281 mL	21.0704 mL
	10 mM	0.4214 mL	2.1070 mL	4.2141 mL	10.5352 mL
	15 mM	0.2809 mL	1.4047 mL	2.8094 mL	7.0235 mL
	20 mM	0.2107 mL	1.0535 mL	2.1070 mL	5.2676 mL
	25 mM	0.1686 mL	0.8428 mL	1.6856 mL	4.2141 mL
	30 mM	0.1405 mL	0.7023 mL	1.4047 mL	3.5117 mL
	40 mM	0.1054 mL	0.5268 mL	1.0535 mL	2.6338 mL
	50 mM	0.0843 mL	0.4214 mL	0.8428 mL	2.1070 mL
	60 mM	0.0702 mL	0.3512 mL	0.7023 mL	1.7559 mL
	80 mM	0.0527 mL	0.2634 mL	0.5268 mL	1.3169 mL
	100 mM	0.0421 mL	0.2107 mL	0.4214 mL	1.0535 mL

MD-3-A45 Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MD-3-A452314337-87-4ERKFGFRExtracellular signal regulated kinasesFibroblast growth factor receptorERK activationchronic kidney diseasehereditary hypophosphatemic ricketsFGF-23HEK-293 cellsfibroblast growth factor 23FGFRs/α-Klotho signalingacquired hypophosphatemic ricketsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *